CordenPharma Commits €900M To Expand Peptide Technology Platform

India Pharma Outlook Team | Wednesday, 17 July 2024

 pharma companies, peptide technology, India Pharma Outlook

CordenPharma, a partner for CDMO services for biotech and pharma companies developing complex modalities, has revealed its most significant strategic investment of approximately €900 million in the next three years to expand its peptide technology platform.

These transformational plans involve two major expansion projects happening simultaneously in the US and Europe, enhancing both current facilities and constructing new ones that adhere to strict quality and technical standards for short and long peptide manufacturing, including requirements for Biologics License Applications (BLA).

The expansion in the US will include the addition of more peptide capacity at the CordenPharma Colorado location, which will involve building a new large-scale manufacturing facility and adding more manufacturing trains to the current facility. This outcome is a direct result of the growing demand for GLP-1 agonist medications used to treat diabetes and obesity, following several multiyear contracts worth approximately €3 billion, with possible additional benefits.

The focus of European expansion revolves around building a cutting-edge greenfield facility to increase peptide capacity in order to support customers ranging from early clinical to late-stage commercial manufacturing. The new location will be in the center of Europe, seamlessly connected to CordenPharma's current facility network.

© 2024 India Pharma Outlook. All Rights Reserved.